XML 85 R41.htm IDEA: XBRL DOCUMENT
v3.22.4

Other gains and losses, and litigation | 12 Months Ended
--- | ---
Dec. 31, 2022
Analysis of income and expense [abstract] |
Other gains and losses, and litigation | Other gains and losses, and litigation Other gains and losses, and litigation for 2022 represent a charge of €370 million, including the pre-tax loss arising on the deconsolidation of EUROAPI (see Note D.1.) and costs related to major litigation, including the estimated future defense costs which Sanofi may be exposed in connection with the Zantac® litigation. For 2021, this line item represented a charge of €5 million. For 2020, this line item represented a net gain of €136 million, mainly relating to the sale of Seprafilm®.

X
- References No definition available. + Details
Name: | ifrs-full_AnalysisOfIncomeAndExpenseAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of other gains and losses, and litigation. + References No definition available. + Details
Name: | sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock
Namespace Prefix: | sny_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration